Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02393456 · ClinicalTrials.gov registry record · Early Phase 1
Oxytocin and the Social Brain
A Early Phase 1 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 161
- Enrollment target
NCT02393456 is a Early Phase 1 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 161 participants.
The verdict
NCT02393456, a Early Phase 1 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 161 participants
- Enrollment target
Study Summary
It has long been established that interpersonal relationships can have a profound impact on health and well-being. Yet, the investigators are still learning about the complex biological processes that contribute to positive social interactions and the ability to develop and maintain social relationships. Recent research has begun to focus on oxytocin, a neuropeptide that is naturally produced in the hypothalamus, because administration of this neuropeptide has been associated with increased trust, generosity, empathy, cooperation, memory of social stimuli (e.g., faces), and brain activity in neural regions associated with social and emotional processes. To date, several aspects of oxytocin's effects on social behavior have been unexplored. As such, the overarching goal of this project is to examine the effects of intranasal oxytocin on several tasks involving social processes. In addition, the investigators will explore associated neural activity through functional magnetic resonance imaging (fMRI). Understanding how oxytocin influences these aspects of social functioning will help to inform research that has begun to establish the potential for use of this neuropeptide in education as well as psychiatric disorders such as autism spectrum disorders and schizophrenia that are characterized by social deficits. The investigators hypothesize that compared to placebo, oxytocin will improve deception detection, increase empathy and altruism, and enhance responses to photo stimuli of primary caregivers. These effects will manifest in behavioral and neural activity. It is also hypothesized that main effects will not be found for oxytocin, but rather, analyses of relevant moderators will elucidate these findings.
Interventions
- DRUG Intranasal oxytocin
- DRUG Intranasal placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02393456
The ClinicalTrials.gov registry entry for NCT02393456 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intranasal oxytocin is the first listed.
NCT02393456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02393456 about?
NCT02393456 is a clinical study titled "Oxytocin and the Social Brain". It has long been established that interpersonal relationships can have a profound impact on health and well-being. Yet, the investigators are still learning about the complex biological processes that contribute to positive social interactions and the ability to develop and maintain social relations...
What is the current status of trial NCT02393456?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 161 participants. The study started on 2015-01. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02393456?
The interventions under investigation include: Intranasal oxytocin (DRUG), Intranasal placebo (DRUG).
Who is sponsoring clinical trial NCT02393456?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.